Overview

Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The present study was conceived to evaluate the effects of levosimendan on cardiopulmonary exercise test (CPET) and DLCO ( Diffusion capacity of Lung for carbon monoxide) in patients with severe heart failure in stable clinical conditions (NYHA - New York Heart Association - class III, with a peak VO2 (Oxygen consumption ) < 12 ml/min/kg) on top of optimized standard therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Centro Cardiologico Monzino
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Simendan